PD-1 is, therefore, a negative regulator of a pre-existing immune response and its blockade has become relevant in cancer therapy because of its potential to reverse T cell exhaustion with subsequent stimulation of anti-tumour immunity. The gene discussed is PDCD1; the disease is neoplasm.